RNAi-话题@MedSci

#RNAi#

47篇内容 | 898人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1751691, encodeId=94851e516910b, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, objectTitle=Science Advances：北理工黄渊余团队开发新型脂质纳米颗粒，递送RNAi疗法，治疗和预防心血管疾病, objectType=article, longId=299292, objectId=4c8c299292ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c8c299292ad, replyNumber=0, likeNumber=38, createdTime=2022-09-06, rootId=0, userName=yinxm8315, userId=d9d436366397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c8c299292ad, moduleTitle=Science Advances：北理工黄渊余团队开发新型脂质纳米颗粒，递送RNAi疗法，治疗和预防心血管疾病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c8c299292ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1751692, encodeId=a3de1e51692a1, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, objectTitle=NEJM发布遗传性肝病RNAi疗法2期临床试验结果，降低致病蛋白83%, objectType=article, longId=730942, objectId=b578e309426a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b578e309426a, replyNumber=0, likeNumber=44, createdTime=2022-07-06, rootId=0, userName=yinxm8315, userId=d9d436366397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b578e309426a, moduleTitle=NEJM发布遗传性肝病RNAi疗法2期临床试验结果，降低致病蛋白83%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b578e309426a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1751690, encodeId=44ba1e51690e7, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, objectTitle=Genet Med:lumasiran治疗原发性1型高草酸尿症的3期试验:一种新的婴幼儿RNAi疗法, objectType=article, longId=294959, objectId=ac9f29495947, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac9f29495947, replyNumber=0, likeNumber=45, createdTime=2022-07-31, rootId=0, userName=yinxm8315, userId=d9d436366397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac9f29495947, moduleTitle=Genet Med:lumasiran治疗原发性1型高草酸尿症的3期试验:一种新的婴幼儿RNAi疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac9f29495947)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1751689, encodeId=8eb71e5168990, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, objectTitle=Nat Med：AAV递送RNAi治疗共济失调惊现脑毒性, objectType=article, longId=219119, objectId=a967219119f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a967219119f3, replyNumber=0, likeNumber=59, createdTime=2022-06-25, rootId=0, userName=yinxm8315, userId=d9d436366397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a967219119f3, moduleTitle=Nat Med：AAV递送RNAi治疗共济失调惊现脑毒性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a967219119f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1751686, encodeId=b5841e516865e, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, objectTitle=RNAi药物治疗乙肝的新药RG6346，疗效强且持久超过1年, objectType=article, longId=203508, objectId=85e2203508d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85e2203508d6, replyNumber=0, likeNumber=53, createdTime=2021-05-17, rootId=0, userName=yinxm8315, userId=d9d436366397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85e2203508d6, moduleTitle=RNAi药物治疗乙肝的新药RG6346，疗效强且持久超过1年, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85e2203508d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1751682, encodeId=7e101e516829e, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, objectTitle=ERA-EDTA 2020：重磅！RNAi疗法Lumasiran治疗高草酸尿症，6个月患者恢复到正常水平, objectType=article, longId=195829, objectId=217019582920, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=217019582920, replyNumber=0, likeNumber=35, createdTime=2021-05-29, rootId=0, userName=yinxm8315, userId=d9d436366397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=217019582920, moduleTitle=ERA-EDTA 2020：重磅！RNAi疗法Lumasiran治疗高草酸尿症，6个月患者恢复到正常水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=217019582920)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1751676, encodeId=f3351e516766b, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, objectTitle=Alynlam的RNAi药物lumasiran治疗原发性高草酸尿症，完成向欧盟和美国的申请, objectType=article, longId=191814, objectId=bcab1918142e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bcab1918142e, replyNumber=0, likeNumber=35, createdTime=2020-07-17, rootId=0, userName=yinxm8315, userId=d9d436366397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bcab1918142e, moduleTitle=Alynlam的RNAi药物lumasiran治疗原发性高草酸尿症，完成向欧盟和美国的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bcab1918142e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1751684, encodeId=78f91e516842d, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, objectTitle=RNAi巨头Alnylam公司再发力：出击非酒精性脂肪性肝炎（NASH）, objectType=article, longId=198731, objectId=37c9198e311c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37c9198e311c, replyNumber=0, likeNumber=35, createdTime=2020-10-15, rootId=0, userName=yinxm8315, userId=d9d436366397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37c9198e311c, moduleTitle=RNAi巨头Alnylam公司再发力：出击非酒精性脂肪性肝炎（NASH）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37c9198e311c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1751685, encodeId=77261e5168500, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, objectTitle=全球第三款RNAi疗法lumasiran即将获批，治疗罕见肝病——1型原发性高草酸尿症, objectType=article, longId=202546, objectId=dae520254669, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dae520254669, replyNumber=0, likeNumber=44, createdTime=2020-12-28, rootId=0, userName=yinxm8315, userId=d9d436366397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dae520254669, moduleTitle=全球第三款RNAi疗法lumasiran即将获批，治疗罕见肝病——1型原发性高草酸尿症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dae520254669)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1751683, encodeId=a7511e51683dd, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, objectTitle=RNAi疗法lumasiran：获得英国MHRA支持治疗1型原发性高草酸尿症, objectType=article, longId=197645, objectId=e51219e64512, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e51219e64512, replyNumber=0, likeNumber=33, createdTime=2021-04-04, rootId=0, userName=yinxm8315, userId=d9d436366397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e51219e64512, moduleTitle=RNAi疗法lumasiran：获得英国MHRA支持治疗1型原发性高草酸尿症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e51219e64512)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1751688, encodeId=29da1e516881a, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, objectTitle=全球第三款RNAi药物出炉，百亿美金市场谁主沉浮？, objectType=article, longId=204189, objectId=8eea2041892b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8eea2041892b, replyNumber=0, likeNumber=42, createdTime=2021-10-03, rootId=0, userName=yinxm8315, userId=d9d436366397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8eea2041892b, moduleTitle=全球第三款RNAi药物出炉，百亿美金市场谁主沉浮？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8eea2041892b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1751674, encodeId=ea0d1e51674b7, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, objectTitle=RNAi治疗COVID-19：Alnylam与Vir Biotechnology联手开发, objectType=article, longId=189413, objectId=9aac1894137a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9aac1894137a, replyNumber=0, likeNumber=31, createdTime=2020-09-28, rootId=0, userName=yinxm8315, userId=d9d436366397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9aac1894137a, moduleTitle=RNAi治疗COVID-19：Alnylam与Vir Biotechnology联手开发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9aac1894137a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1751687, encodeId=8b631e5168768, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, objectTitle=RNAi疗法lumasiran获得欧盟批准治疗1型原发性高草酸尿症, objectType=article, longId=203573, objectId=5fc22035e3b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5fc22035e3b4, replyNumber=0, likeNumber=35, createdTime=2021-01-24, rootId=0, userName=yinxm8315, userId=d9d436366397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5fc22035e3b4, moduleTitle=RNAi疗法lumasiran获得欧盟批准治疗1型原发性高草酸尿症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5fc22035e3b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1751679, encodeId=80c71e5167920, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, objectTitle=Alnylam/Vir宣布推进RNAi疗法VIR-2703，用于抵抗新冠病毒COVID-19, objectType=article, longId=193613, objectId=b78f193613fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b78f193613fa, replyNumber=0, likeNumber=38, createdTime=2021-01-04, rootId=0, userName=yinxm8315, userId=d9d436366397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b78f193613fa, moduleTitle=Alnylam/Vir宣布推进RNAi疗法VIR-2703，用于抵抗新冠病毒COVID-19, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b78f193613fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1751673, encodeId=61581e51673aa, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, objectTitle=RNAi疗法对抗2019-nCoV：Sirnaomics推进基于RNAi的预防和治疗方法, objectType=article, longId=186736, objectId=d207186e36d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d207186e36d7, replyNumber=0, likeNumber=36, createdTime=2020-09-08, rootId=0, userName=yinxm8315, userId=d9d436366397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d207186e36d7, moduleTitle=RNAi疗法对抗2019-nCoV：Sirnaomics推进基于RNAi的预防和治疗方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d207186e36d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1751672, encodeId=ccaf1e5167253, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, objectTitle=FDA批准Alnylam的RNAi疗法givosiran治疗罕见遗传病——急性肝卟啉症, objectType=article, longId=183486, objectId=889518348636, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=889518348636, replyNumber=0, likeNumber=46, createdTime=2020-01-28, rootId=0, userName=yinxm8315, userId=d9d436366397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=889518348636, moduleTitle=FDA批准Alnylam的RNAi疗法givosiran治疗罕见遗传病——急性肝卟啉症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=889518348636)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1751675, encodeId=3db41e516759d, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, objectTitle=Alnylam的第二款RNAi药物Givlaari，获得欧盟批准治疗肝卟啉症, objectType=article, longId=189441, objectId=02d9189441ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02d9189441ee, replyNumber=0, likeNumber=29, createdTime=2020-07-24, rootId=0, userName=yinxm8315, userId=d9d436366397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02d9189441ee, moduleTitle=Alnylam的第二款RNAi药物Givlaari，获得欧盟批准治疗肝卟啉症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02d9189441ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1751678, encodeId=dfc71e51678ca, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, objectTitle=Alnylam的RNAi疗法Vutrisiran获得FDA快速通道指定，治疗hATTR淀粉样变性, objectType=article, longId=192376, objectId=8eeb1923e6a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8eeb1923e6a6, replyNumber=0, likeNumber=37, createdTime=2020-11-02, rootId=0, userName=yinxm8315, userId=d9d436366397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8eeb1923e6a6, moduleTitle=Alnylam的RNAi疗法Vutrisiran获得FDA快速通道指定，治疗hATTR淀粉样变性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8eeb1923e6a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1751681, encodeId=b3f91e51681c1, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, objectTitle=ERA-EDTA 2020：RNAi疗法公司Alnylam再发力！Lumasiran治疗1型原发性高草酸尿症III期临床成功, objectType=article, longId=195493, objectId=6fc619549390, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fc619549390, replyNumber=0, likeNumber=40, createdTime=2020-11-19, rootId=0, userName=yinxm8315, userId=d9d436366397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fc619549390, moduleTitle=ERA-EDTA 2020：RNAi疗法公司Alnylam再发力！Lumasiran治疗1型原发性高草酸尿症III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fc619549390)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1751680, encodeId=2b501e51680cc, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, objectTitle=FDA为Alnylam的RNAi疗法Lumasiran授予优先审查，用于治疗1型原发性高草酸尿症, objectType=article, longId=194823, objectId=beb619482390, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=beb619482390, replyNumber=0, likeNumber=44, createdTime=2021-05-07, rootId=0, userName=yinxm8315, userId=d9d436366397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=beb619482390, moduleTitle=FDA为Alnylam的RNAi疗法Lumasiran授予优先审查，用于治疗1型原发性高草酸尿症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=beb619482390)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

RNAi

2020-05-29

yinxm8315 (审核中...)

前往app查看评论内容

#RNAi#

Science Advances：北理工黄渊余团队开发新型脂质纳米颗粒，递送RNAi疗法，治疗和预防心血管疾病

2022-09-06

yinxm8315 (审核中...)

前往app查看评论内容

#RNAi#

NEJM发布遗传性肝病RNAi疗法2期临床试验结果，降低致病蛋白83%

2022-07-06

yinxm8315 (审核中...)

前往app查看评论内容

#RNAi#

Genet Med:lumasiran治疗原发性1型高草酸尿症的3期试验:一种新的婴幼儿RNAi疗法

2022-07-31

yinxm8315 (审核中...)

前往app查看评论内容

#RNAi#

Nat Med：AAV递送RNAi治疗共济失调惊现脑毒性

2022-06-25

yinxm8315 (审核中...)

前往app查看评论内容

#RNAi#

RNAi药物治疗乙肝的新药RG6346，疗效强且持久超过1年

2021-05-17

yinxm8315 (审核中...)

前往app查看评论内容

#RNAi#

ERA-EDTA 2020：重磅！RNAi疗法Lumasiran治疗高草酸尿症，6个月患者恢复到正常水平

2021-05-29

yinxm8315 (审核中...)

前往app查看评论内容

#RNAi#

Alynlam的RNAi药物lumasiran治疗原发性高草酸尿症，完成向欧盟和美国的申请

2020-07-17

yinxm8315 (审核中...)

前往app查看评论内容

#RNAi#

RNAi巨头Alnylam公司再发力：出击非酒精性脂肪性肝炎（NASH）

2020-10-15

yinxm8315 (审核中...)

前往app查看评论内容

#RNAi#

全球第三款RNAi疗法lumasiran即将获批，治疗罕见肝病——1型原发性高草酸尿症

2020-12-28

yinxm8315 (审核中...)

前往app查看评论内容

#RNAi#

RNAi疗法lumasiran：获得英国MHRA支持治疗1型原发性高草酸尿症

2021-04-04

yinxm8315 (审核中...)

前往app查看评论内容

#RNAi#

全球第三款RNAi药物出炉，百亿美金市场谁主沉浮？

2021-10-03

yinxm8315 (审核中...)

前往app查看评论内容

#RNAi#

RNAi治疗COVID-19：Alnylam与Vir Biotechnology联手开发

2020-09-28

yinxm8315 (审核中...)

前往app查看评论内容

#RNAi#

RNAi疗法lumasiran获得欧盟批准治疗1型原发性高草酸尿症

2021-01-24

yinxm8315 (审核中...)

前往app查看评论内容

#RNAi#

Alnylam/Vir宣布推进RNAi疗法VIR-2703，用于抵抗新冠病毒COVID-19

2021-01-04

yinxm8315 (审核中...)

前往app查看评论内容

#RNAi#

RNAi疗法对抗2019-nCoV：Sirnaomics推进基于RNAi的预防和治疗方法

2020-09-08

yinxm8315 (审核中...)

前往app查看评论内容

#RNAi#

FDA批准Alnylam的RNAi疗法givosiran治疗罕见遗传病——急性肝卟啉症

2020-01-28

yinxm8315 (审核中...)

前往app查看评论内容

#RNAi#

Alnylam的第二款RNAi药物Givlaari，获得欧盟批准治疗肝卟啉症

2020-07-24

yinxm8315 (审核中...)

前往app查看评论内容

#RNAi#

Alnylam的RNAi疗法Vutrisiran获得FDA快速通道指定，治疗hATTR淀粉样变性

2020-11-02

yinxm8315 (审核中...)

前往app查看评论内容

#RNAi#

ERA-EDTA 2020：RNAi疗法公司Alnylam再发力！Lumasiran治疗1型原发性高草酸尿症III期临床成功

2020-11-19

yinxm8315 (审核中...)

前往app查看评论内容

#RNAi#

FDA为Alnylam的RNAi疗法Lumasiran授予优先审查，用于治疗1型原发性高草酸尿症

2021-05-07

科室
- - 订阅+
  - 更多科室
工具
服务